June 4, 2026

On the morning of June 4, 2026, a Zhihe delegation led by Chairman Dr. Zhang Zhefeng, Vice Chair Hou Wen, Chief AI Scientist Dr. Dai Yujie, Head of Molecular Design Research Institute Dr. Fu Haijian, AI Center backbone members, and the IT head visited Qilin Science and Technology Innovation Park.

They held in-depth discussions with Qilin S&T Bureau Director Liu Jing and Nanjing Zhongke Nishang Technology General Manager Wang Chong on AI applications in innovative-drug R&D.

Zhihe Vice President, Chief Peptide Scientist, and AI Center Head Dr. Ding Wei participated online from Macau University of Science and Technology.

(1) Both Sides Engage in In-Depth Exchange on AI Innovative-Drug Directions

At the meeting, both sides had in-depth discussions on AI applications in innovative-drug R&D.

The Zhihe team presented the AI innovative-drug platform construction plan, covering platform positioning, technical architecture, and computing support.

Both sides agreed that AI can significantly improve drug R&D efficiency, reduce costs, and has broad application prospects in innovative drugs.

Qilin S&T Innovation Park expressed full support for Zhihe's AI innovative-drug platform and committed to providing relevant support and services.

(2) On-Site Visit to the Nanjing Intelligent Computing Center

After the meeting, Zhihe visited the Nanjing Intelligent Computing Center.

The center is equipped with advanced computing infrastructure that can provide strong computing support for the AI innovative-drug platform.

During the visit, both sides had in-depth discussions on computing resource allocation, technical support, and cooperation models.

(3) Both Sides Look Ahead to Deepened Future Cooperation

This exchange marks a solid step forward in Zhihe's cooperation with Qilin S&T Innovation Park in the AI innovative-drug field.

Both sides agreed that AI technology has broad prospects and huge cooperation potential in innovative-drug R&D.

Going forward, both sides will strengthen communication, deepen pragmatic cooperation, and jointly promote the AI innovative-drug platform.

This will contribute to the high-quality development of the pharmaceutical industry.

Zhihe will take this cooperation as an opportunity to leverage its strengths in innovative-drug molecular design and translation, working closely with the AI team.

Together they will build a domestically leading AI innovative-drug molecular design and clinical-trial platform.

Guided by the mission of "AI empowering innovation" and the vision of "innovation for humanity," the company will...

Take solving "unmet clinical needs" as its mission.

Dedicate to applying the latest advances in AI and biomedical science to Category 1 innovative drugs with breakthrough efficacy expectations.

Benchmark international frontiers and commit to independent innovation, starting from the global high ground in the relevant therapeutic area, to develop blockbuster FIC compounds.

Accelerate building an IP-rich new-drug compound library and core improved-innovation technology platforms.

Provide innovation-driven core momentum for domestic and international pharmaceutical companies.

Insist on compliant operations and strong IP protection to ensure steady platform construction and inject strong momentum into innovative-drug R&D.

About Zhihe

Nanjing Zhihe Pharmaceutical Technology Co., Ltd., established in 2018 in Nanjing Gulou District, is a CXO company founded by leading industry experts, providing professional drug R&D technical services.

Guided by clinical demand, innovation, and customer needs, the company provides high-quality, efficient one-stop services including corporate strategy and market-cap management, product portfolio assessment and pipeline planning, pharmaceutical research, nonclinical study design and project management, clinical research, and regulatory filing.

Through high-quality, efficient, cost-effective R&D services, the company helps clients seize opportunities in consistency evaluation, MAH policy, and centralized procurement.

Empowering enterprise growth, partners have all achieved rapid high-quality development.

In recent years, the company has strengthened CXO capacity in Beijing, Heze (Shandong), and Shijiazhuang (Hebei).

"Beijing Zhihe Aikang," "Shandong Ruzhi Biotech," and "Shijiazhuang Dishikaiwei" were established.

These subsidiaries aim to provide closer, high-quality services to customers and create service synergy with Nanjing Zhihe for complementary advantages.

The TCM Research Institute, Improved Innovation Research Institute, and Peptide Innovation Institute strengthen Zhihe's growth in key and white-space CRO areas.

It is also a professional CMO/CDMO base with nearly 12 production lines, including integrated vial lyophilization/aqueous injection, BFS aqueous injection/inhalation solution, BFS eye drops, hormonal nebulized inhalation, antitumor liposome, antitumor BFS aqueous injection, prefilled syringe, and oral solution/syrup lines.

The company owns high-precision scientific instruments, including more than 160 sets of HPLC, LC-MS, and other precision instruments from Agilent, Shimadzu, and Thermo Fisher.

It has full formulation R&D equipment for APIs, peptides, tablets, injections, topical preparations, inhaled preparations, and ophthalmic preparations.

The company has full-chain drug-development capability across multiple dosage forms, from preclinical PCC, API, formulation CMC, to clinical services.

The company has established multiple municipal R&D platforms, including the Nanjing Engineering Technology Research Center.

It holds honors including ISO 9001 quality system certification, Jiangsu Provincial Sci-Tech SME, Jiangsu Three-Star Cloud Enterprise, Jiangsu Private Sci-Tech Enterprise, Excellent Enterprise of the Jiangsu Entrepreneurship Competition, Nanjing Innovative SME, National High-Tech Enterprise, Jiangsu Provincial Specialized and Sophisticated SME, and National Specialized and Sophisticated "Little Giant".